MINI REVIEW article
Front. Bioeng. Biotechnol.
Sec. Nanobiotechnology
Volume 13 - 2025 | doi: 10.3389/fbioe.2025.1635747
This article is part of the Research TopicNanotechnology-Based Delivery Systems for Cancer TreatmentView all 6 articles
Reprogramming the Tumor-Immune Landscape via Nanomaterial-Induced Immunogenic Cell Death: A Mini Review
Provisionally accepted
- Binzhou Medical University, Binzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Nanomaterial-induced immunogenic cell death (ICD) represents a transformative approach to overcoming limitations of conventional cancer immunotherapies. Unlike traditional methods hindered by systemic toxicity and inadequate targeting, nanomaterials precisely deliver therapeutic agents and effectively modulate tumor microenvironmental factors, including hypoxia, acidity, and redox imbalance. By triggering ICD through mechanisms such as reactive oxygen species generation, tumor acidity neutralization, and hypoxia alleviation, nanomaterials facilitate potent anti-tumor immune responses, enhance dendritic cell activation, and promote cytotoxic T lymphocyte recruitment. Additionally, integrating nanomaterial-induced ICD with established immunotherapies like checkpoint inhibitors and CAR-T cells has shown promising preclinical synergy, enabling robust and lasting antitumor immunity. Despite significant translational challenges related to safety, standardization, and tumor heterogeneity, continued advances in multifunctional nanoplatform development and personalized therapeutic strategies hold substantial promise for improving cancer treatment outcomes.
Keywords: Immunogenic cell death (ICD), nanomaterials, Tumor microenvironment (TME), cancer immunotherapy, Targeted Drug Delivery
Received: 27 May 2025; Accepted: 30 Jun 2025.
Copyright: © 2025 Qu, Meng, Che and Yi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaoyang Qu, Binzhou Medical University, Binzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.